IDEAYA Biosciences (NASDAQ:IDYA) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of IDEAYA Biosciences (NASDAQ:IDYA) from a buy rating to a sell rating in a research report released on Saturday.

Other equities research analysts have also issued reports about the stock. Guggenheim reissued a “buy” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. UBS Group started coverage on shares of IDEAYA Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Mizuho increased their price objective on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $49.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.69.

IDEAYA Biosciences Stock Up 0.4%

Shares of IDYA opened at $32.11 on Friday. The stock has a market cap of $2.82 billion, a PE ratio of -24.51 and a beta of 0.10. IDEAYA Biosciences has a 12-month low of $13.45 and a 12-month high of $39.28. The business has a 50-day simple moving average of $34.17 and a two-hundred day simple moving average of $30.67.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.09. The firm had revenue of $21.75 million for the quarter, compared to the consensus estimate of $5.95 million. During the same quarter last year, the firm posted ($1.49) earnings per share. The business’s revenue for the quarter was up 55.7% on a year-over-year basis. On average, equities research analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current year.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds have recently added to or reduced their stakes in IDYA. Farther Finance Advisors LLC lifted its stake in IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in shares of IDEAYA Biosciences during the 3rd quarter valued at $38,000. ANTIPODES PARTNERS Ltd lifted its position in shares of IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the period. Abich Financial Wealth Management LLC bought a new position in IDEAYA Biosciences during the third quarter worth $58,000. Finally, Elevation Point Wealth Partners LLC bought a new position in IDEAYA Biosciences during the second quarter worth $61,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.